Cannabinoid Poisoning Differential Diagnoses

1. Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 2003 Jan 22-29. 289(4):427-33. [Medline].

2. Tarter RE, Kirisci L, Mezzich A, Ridenour T, Fishbein D, Horner M, et al. Does the "gateway" sequence increase prediction of cannabis use disorder development beyond deviant socialization? Implications for prevention practice and policy. Drug Alcohol Depend. 2012 Jun. 123 Suppl 1:S72-8. [Medline]. [Full Text].

3. Wells DL, Ott CA. The "new" marijuana. Ann Pharmacother. 2011 Mar. 45(3):414-7. [Medline].

4. M.A. Costa, B.M. Fonseca, F. Marques, N.A. Teixeira, G. Correia-da-Silva. The psychoactive compound of Cannabis sativa, Δ9-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 6 August 2015. 33:94-103. [Medline]. [Full Text].

5. Torri D. Metz, Elaine H. Stickrath. Marijuana use in pregnancy and lactation: a review of the evidence. American Journal of Obstetrics and Gynecology. December 2015. 213:761-778. [Medline]. [Full Text].

6. Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011 Mar 1. 342:d738. [Medline]. [Full Text].

7. Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction. 2003 Nov. 98(11):1493-504. [Medline].

8. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002 Nov 23. 325 (7374):1199. [Medline].

9. Fitzgerald KT, Bronstein AC, Newquist KL. Marijuana poisoning. Top Companion Anim Med. 2013 Feb. 28(1):8-12. [Medline].

10. Wiegand TJ, Wax PM, Schwartz T, Finkelstein Y, Gorodetsky R, Brent J. The Toxicology Investigators Consortium Case Registry--the 2011 experience. J Med Toxicol. 2012 Dec. 8(4):360-77. [Medline].

11. National Institute on Drug Abuse, National Institutes of Health, Centers for Substance Abuse Prevention and Treatment. National Conference on Marijuana Use: Prevention, VA. Treatment and Research. NIH publication. 1995: Arlington. 38-49:no 96-4106. [Full Text].

12. Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction. 2002 Jun. 97(6):621-32. [Medline].

13. Marijuana. National Institute on Drug Abuse. Available at http://www.drugabuse.gov/drugs-abuse/marijuana. March 2014; Accessed: August 11, 2015.

14. What is the scope of marijuana use in the United States?. National Institute on Drug Abuse. Available at http://www.drugabuse.gov/publications/research-reports/marijuana/what-scope-marijuana-use-in-united-states. June 2015; Accessed: August 11, 2015.

15. Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. The DAWN Report. Available at http://www.samhsa.gov/data/sites/default/files/DAWN127/DAWN127/sr127-DAWN-highlights.htm. February 22, 2013; Accessed: August 11, 2015.

16. Eurosurveillance Editorial Team. European Drug Report 2013: trends and developments. Eurosurveillance, The European Monitoring Centre for Drugs and Drug Addiction. 30 May 2013. Available at www.eurosurveillance.org.

17. UNODC. World Drug Report 2014: Cannabis. United Nations Office on Drugs and Crime. Available at http://www.unodc.org/wdr2014/en/cannabis.html. June 26, 2014; Accessed: August 11, 2015.

18. Jessica B. Hancock-Allen, MSN; Lisa Barker; Michael VanDyke, PhD; Dawn B. Holmes, MD. Notes from the Field: Death Following Ingestion of an Edible Marijuana Product — Colorado, March 2014. CDC Morbidity and Mortality Weekly Report. 24 July 2015. Available at www.cdc.gov.

19. Kim HS, Anderson JD, Saghafi O, Heard KJ, Monte AA. Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med. 2015 Jun. 22 (6):694-9. [Medline]. [Full Text].

20. Huestis MA, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol. 1995 Oct. 19(6):443-9. [Medline].

21. Taylor, M., Lees, R., Henderson, G., et al. Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users. Drug and Alcohol Review. 14 June 2016. Epub ahead of print:[Medline]. [Full Text].

22. Hooper SR, Woolley D, De Bellis MD. Intellectual, neurocognitive, and academic achievement in abstinent adolescents with cannabis use disorder. Psychopharmacology (Berl). 2014 Apr. 231 (8):1467-77. [Medline].

23. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012 Oct 2. 109 (40):E2657-64. [Medline].

24. Bechtold J, Simpson T, White HR, Pardini D. Chronic Adolescent Marijuana Use as a Risk Factor for Physical and Mental Health Problems in Young Adult Men. Psychol Addict Behav. 2015 Aug 3. [Medline].

25. Brooks M. Teen Marijuana Use Not Harmful?. Medscape Medical News. Available at http://www.medscape.com/viewarticle/849337. August 11, 2015; Accessed: August 11, 2015.

26. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996 Nov. 91(11):1585-614. [Medline].

27. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. 1999 Oct. 83(4):637-49. [Medline].

28. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001 Feb. 178:101-6. [Medline].

29. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA. 2004 May 5. 291(17):2114-21. [Medline].

30. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003. 42(4):327-60. [Medline].

31. Hall W, Solowij N. Adverse effects of cannabis. Lancet. 1998 Nov 14. 352(9140):1611-6. [Medline].

32. Hall W, Solowij N, Lemon J:. The Health and Psychological Consequences of Cannabis Use. Monograph No 25. National Drug Strategy. Australian Government Publication Serv. 1994. 15-20.

33. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990 Mar. 87(5):1932-6. [Medline].

34. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Aug. 28(5):849-63. [Medline].

35. Khalsa JH, Genser S, Francis H, Martin B. Clinical consequences of marijuana. J Clin Pharmacol. 2002 Nov. 42(11 Suppl):7S-10S. [Medline].

36. Kilpatrick DG, Acierno R, Saunders B, Resnick HS, Best CL, Schnurr PP. Risk factors for adolescent substance abuse and dependence: data from a national sample. J Consult Clin Psychol. 2000 Feb. 68(1):19-30. [Medline].

37. McGee R, Williams S, Poulton R, Moffitt T. A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction. 2000 Apr. 95(4):491-503. [Medline].

38. McGuigan M. Cannabinoids. Goldfrank’s Toxicological Emergencies. 8th ed. New York: McGraw-Hill Professional; 2006.

39. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001 Oct. 58(10):909-15. [Medline].

40. Vitale S, van de Mheen D. Illicit drug use and injuries: A review of emergency room studies. Drug Alcohol Depend. 2006 Mar 15. 82(1):1-9. [Medline].

41. Wallace KL, Kunkel DB. Legal hemp products and urine cannabinoid testing. J Toxicol Clin Toxicol. 1999. 37(7):897-8. [Medline].

42. Watson SJ, Benson JA Jr, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. 2000 Jun. 57(6):547-52. [Medline].

Linda Russo, MD Resident Physician, Department of Emergency Medicine, Kings County Hospital Center, State University of New York Downstate Medical Center

Linda Russo, MD is a member of the following medical societies: American Academy of Emergency Medicine, American Medical Association, Emergency Medicine Residents' Association

Disclosure: Nothing to disclose.

Sage W Wiener, MD Assistant Professor, Department of Emergency Medicine, State University of New York Downstate Medical Center; Director of Medical Toxicology, Department of Emergency Medicine, Kings County Hospital Center

Sage W Wiener, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Duane C Caneva, MD, MSc Senior Medical Advisor to Customs and Border Protection, Department of Homeland Security (DHS) Office of Health Affairs; Federal Co-Chair, Health, Medical, Responder Safety Subgroup, Interagency Board (IAB)

Disclosure: Nothing to disclose.

Suzanne White, MD Medical Director, Regional Poison Control Center at Children's Hospital, Program Director of Medical Toxicology, Associate Professor, Departments of Emergency Medicine and Pediatrics, Wayne State University School of Medicine

Suzanne White, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Clinical Toxicology, American College of Epidemiology, American College of Medical Toxicology, American Medical Association, Michigan State Medical Society

Disclosure: Nothing to disclose.

Jessica A Fulton, DO Assistant Professor of Emergency Medicine, Assistant Residency Director, New York University and Bellevue Hospital Center; Medical Director of Chemical Biological Radiological Nuclear Explosives (CBRNE) Academy, Bellevue Hospital Center and New York City Department of Health and Mental Hygiene

Jessica A Fulton, DO is a member of the following medical societies: American College of Medical Toxicology

Disclosure: Nothing to disclose.

Ani Aydin, MD Resident Physician, Department of Emergency Medicine, Bellevue Hospital/New York University Medical Center

Ani Aydin, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Emergency Physicians, American Medical Association, Society for Academic Emergency Medicine, Emergency Medicine Residents' Association

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors, Gregory R Bell, MD, and Alan H Hall, MD, to the development and writing of this article.

• Print this section
• Print the entire contents of